JOP20220334A1 - مركبات بيوتيل حلقي دايهيدروكينولين سلفوناميد - Google Patents

مركبات بيوتيل حلقي دايهيدروكينولين سلفوناميد

Info

Publication number
JOP20220334A1
JOP20220334A1 JOP/2022/0334A JOP20220334A JOP20220334A1 JO P20220334 A1 JOP20220334 A1 JO P20220334A1 JO P20220334 A JOP20220334 A JO P20220334A JO P20220334 A1 JOP20220334 A1 JO P20220334A1
Authority
JO
Jordan
Prior art keywords
compounds
dihydroquinoline
cyclobutyl
sulfonamide compounds
formula
Prior art date
Application number
JOP/2022/0334A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20220334A1 publication Critical patent/JOP20220334A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

يتعلق هذا الاختراع بمركب بيوتيل حلقي دايهيدروكينولين سلفوناميد له الصيغة إنانتيومير أو دياستيريومير أو أتروبايزومير منه، خليط منهم، أو ملح مقبول صيدلانيًا منه، والذي يُثَبِّط قنوات الصوديوم المعتمدة على الجهد، وبالأخص Nav1.7. تكون المركبات مفيدة لعلاج أمراض مرتبطة بنشاط قنوات الصوديوم مثل اضطرابات الألم، السُعال، والحكة. كما يوفّر هذا الاختراع تركيبات صيدلانية تحتوي على مركبات هذا الاختراع. كما يوفّر أيضًا تحضيرًا انتقائيًا للأتروبي للمركبات المذكورة التي لها الصيغة (I)، ومركبات وسيطة منها.
JOP/2022/0334A 2020-06-10 2021-06-10 مركبات بيوتيل حلقي دايهيدروكينولين سلفوناميد JOP20220334A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037001P 2020-06-10 2020-06-10
PCT/US2021/036896 WO2021252820A1 (en) 2020-06-10 2021-06-10 Cyclobutyl dihydroquinoline sulfonamide compounds

Publications (1)

Publication Number Publication Date
JOP20220334A1 true JOP20220334A1 (ar) 2023-01-30

Family

ID=76797115

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0334A JOP20220334A1 (ar) 2020-06-10 2021-06-10 مركبات بيوتيل حلقي دايهيدروكينولين سلفوناميد

Country Status (19)

Country Link
US (2) US20220306604A1 (ar)
EP (1) EP4165024A1 (ar)
JP (1) JP2021195368A (ar)
KR (1) KR20230022996A (ar)
CN (1) CN115697971A (ar)
AR (1) AR122592A1 (ar)
AU (1) AU2021288696A1 (ar)
BR (1) BR112022025201A2 (ar)
CA (1) CA3183889A1 (ar)
CL (1) CL2022003499A1 (ar)
CO (1) CO2022017903A2 (ar)
CR (1) CR20220631A (ar)
IL (1) IL298325A (ar)
JO (1) JOP20220334A1 (ar)
MX (1) MX2022015856A (ar)
PE (1) PE20230860A1 (ar)
TW (1) TW202214586A (ar)
UY (1) UY39263A (ar)
WO (1) WO2021252820A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
US9776995B2 (en) 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
MX2018007511A (es) * 2015-12-18 2018-09-18 Amgen Inc Compuestos de alquinil dihidroquinolina sulfonamida.
WO2017106871A1 (en) * 2015-12-18 2017-06-22 Amgen Inc. Alkyl dihydroquinoline sulfonamide compounds
EP3440056A4 (en) * 2016-03-21 2019-11-27 The Scripps Research Institute PD (II) -CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C (SP3) H BINDING ACTIVATION

Also Published As

Publication number Publication date
IL298325A (en) 2023-01-01
PE20230860A1 (es) 2023-05-30
CN115697971A (zh) 2023-02-03
EP4165024A1 (en) 2023-04-19
UY39263A (es) 2021-11-30
CR20220631A (es) 2023-01-23
CA3183889A1 (en) 2021-12-16
TW202214586A (zh) 2022-04-16
JP2021195368A (ja) 2021-12-27
CO2022017903A2 (es) 2022-12-20
BR112022025201A2 (pt) 2023-02-28
US20220306604A1 (en) 2022-09-29
MX2022015856A (es) 2023-01-24
US20210387978A1 (en) 2021-12-16
AR122592A1 (es) 2022-09-21
CL2022003499A1 (es) 2023-08-04
WO2021252820A1 (en) 2021-12-16
AU2021288696A1 (en) 2022-12-15
KR20230022996A (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
CR20220631A (es) Compuestos de dihidroquinolinsulfonamida de ciclobutilo
MX2022015622A (es) Compuestos de dihidroquinolin sulfonamida de ciclopropilo.
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
PH12017501570B1 (en) Bicyclic ketone sulfonamide compounds
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
GB0112348D0 (en) Compounds
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
SE9901573D0 (sv) New compounds
MX2024003459A (es) Metodos de tratamiento de trastornos metabolicos.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2022006470A (es) Tiromimeticos novedosos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
RU2685502C2 (ru) Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств
SE9901572D0 (sv) New compounds
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).